- Condition: Endometriosis
Intervention: Drug: Visanne (Dienogest, BAY86-5258)
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Contraception
Interventions: Drug: Flexi ring FR01; Drug: Flexi ring FR20; Drug: Ultra low dose levonorgestrel contraceptive system (LCS)
Sponsors: Bayer; Bayer
Completed - verified May 2012 - Condition: Contraception
Interventions: Drug: Levonorgestrel (Mirena, BAY86-5028); Device: Copper IUD
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin (Scilin N, BAY81-9924); Drug: Insulin (Scilin R _BAY81-9924; Drug: Insulin(Scilin M30_BAY81-9924)
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Renal Cell Carcinoma
Intervention: Other: No intervention
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Brain Ischemia
Intervention: Drug: Rivaroxaban (Xarelto_ BAY59-7939)
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Brain Ischemia
Intervention: Drug: Rivaroxaban(Xarelto_ BAY59-7939)
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus Type 2
Intervention:
Sponsors: GWT-TUD GmbH; GWT-TUD GmbH; Bayer
Not yet recruiting - verified May 2012 - Condition: Appetite
Intervention: Other: No Drug / BAY 11-2233
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Breast Neoplasms
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Eribulin
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Diabetes
Intervention: Device: Contour TS Blood Glucose Monitoring System
Sponsors: Bayer HealthCare, Diabetes Care; Bayer HealthCare, Diabetes Care
Enrolling by invitation - verified April 2012 - Condition: Small Cell Lung Carcinoma
Interventions: Drug: BAY1000394; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Pneumonia, Bacterial
Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939); Drug: Ciprofloxacin (Cipro, BAYQ3939)
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Neurovascular Diseases
Intervention:
Sponsors: Rennes University Hospital; Rennes University Hospital
Not yet recruiting - verified March 2012 - Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Platelet Aggregation
Interventions: Drug: Plavix® and PA32540; Drug: EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Sponsors: POZEN; POZEN
Completed - verified March 2012 - Condition: Headache
Interventions: Drug: BAY1019036; Drug: Acetaminophen; Drug: Placebo
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Diabetes
Intervention: Device: Five Blood Glucose Monitoring Systems
Sponsors: Bayer HealthCare, Diabetes Care; Bayer HealthCare, Diabetes Care
Completed - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Acarbose (Glucobay ODT, BAYG5421); Drug: Acarbose (Glucobay, BAYG5421)
Sponsors: Bayer; Bayer
Active, not recruiting - verified May 2012 - Condition: Papulopustular Rosacea
Interventions: Drug: Azelaic Acid; Drug: Vehicle Foam
Sponsors: Intendis GmbH; Intendis GmbH
Not yet recruiting - verified March 2012 - Condition: Prostatic Neoplasms
Interventions: Drug: BAY88-8223 (Radium-223 chloride); Drug: BAY88-8223 (Radium-223 chloride)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadobutrol (Gadavist, BAY86-4875)
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2012 - Condition: Respiratory System
Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939); Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939); Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939); Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Conditions: Multiple Sclerosis (MS); Inflammatory Disease
Intervention: Other: USPIO MRI - Gadolinium MRI
Sponsors: Rennes University Hospital; Rennes University Hospital; Bayer
Recruiting - verified March 2012 - Condition: Acute Myeloid Leukemia
Intervention: Drug: sorafenib, vorinostat and bortezomib
Sponsors: Indiana University; Indiana University; Millennium Pharmaceuticals, Inc.; Bayer; Merck
Recruiting - verified February 2012 - Conditions: Prophylaxis, Thromboembolism, Venous; Total Knee Replacement; Total Hip Replacement
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Allergic Contact Eczema
Intervention: Drug: Adventan® (methylprednisolone aceponate 0,1%)
Sponsors: Fundacion IMIM; Fundacion IMIM; Adknoma Health Research; Bayer Dermatology
Not yet recruiting - verified February 2012 - Condition: Hypertension
Interventions: Drug: Nifedipine (Adalat, BAYA1040); Drug: Amlodipine (Norvasc); Drug: Diovan
Sponsors: Bayer; Bayer
Completed - verified January 2012 - Condition: Pulmonary Embolism
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Unfractionated heparin; Drug: Warfarin
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Deep Vein Thrombosis
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Unfractionated heparin; Drug: Warfarin
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 chloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified April 2012 - Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis PatientsCondition: Hyperphosphatemia
Intervention: Drug: Lanthanum Carbonate (BAY77-1931)
Sponsors: Bayer; Bayer
Completed - verified January 2012 - Condition: Hyperphosphatemia
Interventions: Drug: Lanthanum carbonate (BAY77-1931); Drug: Calcium carbonate
Sponsors: Bayer; Bayer
Completed - verified January 2012 - Condition: Macular Edema
Intervention: Biological: VEGF Trap-Eye (BAY86-5321)
Sponsors: Bayer; Bayer; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Major Cutaneous Abscess; Cellulitis; Erysipelas
Intervention: Drug: TR701 FA
Sponsors: Trius Therapeutics, Inc.; Trius Therapeutics, Inc.; Bayer
Recruiting - verified January 2012 - Condition: Type 2 Diabetes
Interventions: Drug: "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)]; Drug: Insulin glargine, metformin, prandial insulin
Sponsors: University of Washington; University of Washington; Eli Lilly and Company; Sanofi-Aventis; Amylin Pharmaceuticals, Inc.; DexCom, Inc.; Bayer; Medicomp; University of Texas; Department of Veterans Affairs; Biomedical Research Institute of New Mexico
Not yet recruiting - verified February 2012 - Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY 43-9006)
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Sorafenib
Sponsors: University of California, San Diego; Thomas Kipps; Bayer
Recruiting - verified January 2012 - Condition: Endometrial Hyperplasia
Interventions: Drug: LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland; Drug: Norethisterone Acetate tablets
Sponsors: Mansoura University; Mansoura University
Completed - verified December 2011 - Condition: Pain, Postoperative
Interventions: Drug: BAY98-7111; Drug: Naproxen Sodium (Aleve, BAYH-6689); Drug: Diphenhydramine
Sponsors: Bayer; Bayer
Completed - verified March 2012 - Conditions: Liver Cirrhosis; Carcinoma, Hepatocellular
Intervention:
Sponsors: Asan Medical Center; Jae Ho Byun; Bayer
Recruiting - verified January 2012 - Condition: Hepatocellular Carcinoma
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Infertility
Interventions: Drug: Nimodipine; Drug: Placebo
Sponsors: Mount Sinai Hospital, Canada; Mount Sinai Hospital, Canada
Not yet recruiting - verified April 2012 - Condition: Superficial Vein Thrombosis
Interventions: Drug: Rivaroxaban; Drug: Fondaparinux
Sponsors: GWT-TUD GmbH; GWT-TUD GmbH; Bayer
Recruiting - verified April 2012 - Condition: Biological Availability
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521)
Sponsors: Bayer; Bayer
Completed - verified April 2012 - Condition: Venous Thrombosis
Interventions: Drug: Warfarin (Coumadin); Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Placebo; Drug: Vitamin K (Konakion)
Sponsors: Bayer; Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified March 2012 - Condition: Follicular Lymphoma
Interventions: Drug: 90Y Ibritumomab tiuxetan; Drug: Rituximab
Sponsors: Christie Hospital NHS Foundation Trust; Christie Hospital NHS Foundation Trust; Bayer
Active, not recruiting - verified December 2011 - Condition: Macular Degeneration
Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Drug: Visudyne
Sponsors: Bayer; Bayer; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Type-II Diabetes Mellitus
Intervention: Drug: Acarbose
Sponsors: The Catholic University of Korea; The Catholic University of Korea; Bayer
Not yet recruiting - verified October 2011 - Conditions: Contraception; Pain
Interventions: Drug: Insertion of nitroglycerin ointment; Drug: Insertion of placebo ointment
Sponsors: Oregon Health and Science University; Oregon Health and Science University; American College of Obstetricians and Gynecologists; Bayer
Recruiting - verified December 2011 - Conditions: Carcinoma, Hepatocellular; Liver Dysfunction
Interventions: Drug: Gd-EOB-DTPA; Drug: Gd-EOB-DTPA; Device: MRI; Device: MRI
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Bayer; Seoul St. Mary's Hospital; Asan Medical Center; Chonnam National University Hospital
Recruiting - verified December 2011 - Condition: Liver Carcinoma
Interventions: Drug: sorafenib; Drug: SIR-Sphere
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Ministry of Health, France
Recruiting - verified November 2011 - Condition: Hypertension, Pulmonary
Intervention: Drug: Iloprost (Ventavis inhaled, BAYQ6256)
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Other: Iloprost (Ventavis inhaled, BAYQ6256); Other: Iloprost (Ventavis inhaled, BAYQ6256)
Sponsors: Bayer; Bayer; Dra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain)
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Intervention: Other: No Intervention
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Acarbose; Drug: Placebo
Sponsors: Indiana University; Indiana University School of Medicine; Bayer
Completed - verified November 2011 - Condition: Pharyngitis
Interventions: Drug: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo; Drug: Acetaminophen + placebo; Drug: Placebo
Sponsors: Bayer; Bayer
Completed - verified May 2012 - Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Montefiore Medical Center; State University of New York - Downstate Medical Center; NYU MEDICAL CENTER; University of Rochester; Weill Medical College of Cornell University; Stamford Hospital
Recruiting - verified March 2012 - Conditions: Metabolic Disease; Diabetes Mellitus
Interventions: Other: No drug; Other: No drug
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Peripheral Arterial Disease
Intervention: Drug: Iloprost (Ilomedin, BAYQ6256)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Wet Macular Degeneration
Intervention: Drug: Anti-VEGF injections
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Diabetes
Intervention: Device: Tatsu/Tradewind Investigational BG Monitoring System
Sponsors: Bayer HealthCare, Diabetes Care; Bayer HealthCare, Diabetes Care
Completed - verified April 2012 - Condition: Diabetes
Intervention: Other: Perceived BG value versus measured BG
Sponsors: Bayer HealthCare, Diabetes Care; Bayer HealthCare, Diabetes Care
Completed - verified January 2012 - Conditions: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Anemia
Interventions: Drug: BAY85-3934; Drug: Placebo
Sponsors: Bayer; Bayer
Completed - verified December 2011 - Condition: Ophthalmology, Macular Degeneration
Intervention: Drug: Ranibizumab
Sponsors: Bayer; Bayer
Active, not recruiting - verified February 2012 - Condition: Haemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Neoplasms
Interventions: Drug: Gemcitabine; Drug: BAY80-6946; Drug: Cisplatin; Drug: NaCl; Drug: BAY80-6964 fixed dose
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Therapeutic Equivalency
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors: Bayer; Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified January 2012 - Condition: Contraception
Intervention: Drug: LCS (Levonorgestrel IUS, BAY86-5028)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Diabetes Mellitus
Interventions: Device: Self monitoring blood glucose system; Device: Self monitoring blood glucose system
Sponsors: Abbott Diabetes Care; Abbott Diabetes Care
Active, not recruiting - verified March 2012 - Condition: Cirrhosis of Liver
Intervention:
Sponsors: Asan Medical Center; Asan Medical Center; Bayer
Recruiting - verified May 2012 - Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: sorafenib
Sponsors: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Not yet recruiting - verified October 2011 - Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: Everolimus; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Novartis
Not yet recruiting - verified February 2012 - Condition: Oncology
Intervention: Drug: BAY94-9343
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Pain
Intervention: Drug: Naproxen Sodium ER (BAYH6689)
Sponsors: Bayer; Bayer
Completed - verified February 2012 - Condition: Cardiovascular Disease, Coronary Artery Disease
Interventions: Drug: UFH; Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Rivaroxaban (Xarelto, BAY59-7939) and UFH
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Hyperphosphatemia
Intervention: Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Heart Failure
Interventions: Drug: BAY94-8862 + Placebo + Eplerenone; Drug: BAY94-8862 + Placebo + Eplerenone; Drug: BAY94-8862 + Placebo + Eplerenone; Drug: BAY94-8862 + Placebo + Eplerenone; Drug: BAY94-8862 + Placebo + Eplerenone
Sponsors: Bayer; Bayer
Completed - verified November 2011 - Condition: Pneumonia
Intervention: Other: No Drug
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Diagnostic Imaging
Intervention: Drug: Iopromide (Ultravist, BAY86-4877)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Sponsors: Bayer; Bayer
Completed - verified November 2011 - Conditions: Human Microbiome; Metagenome; Contraception; Cytokine
Intervention:
Sponsors: University of Utah; University of Utah; Bayer
Active, not recruiting - verified January 2012 - Condition: Contraception
Intervention: Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Sponsors: Bayer; Bayer
Active, not recruiting - verified April 2012 - Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer
Completed - verified April 2012 - Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention: Drug: colecalciferol
Sponsors: University of Turku; University of Turku; Bayer
Completed - verified September 2011 - Condition: Hyperphosphatemia
Intervention: Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Diagnostic Imaging
Intervention: Drug: Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Sponsors: Bayer; Bayer
Completed - verified August 2011 - Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer
Completed - verified April 2012 - Condition: Diabetes
Intervention: Device: Ninja 2 Investigational Blood Glucose Monitoring System
Sponsors: Bayer HealthCare, Diabetes Care; Bayer HealthCare, Diabetes Care
Completed - verified April 2012 - Conditions: Myocardial Perfusion Imaging; Magnetic Resonance Imaging
Interventions: Drug: Gadobutrol (Gadavist,Gadovist, BAY86-4875); Drug: Gadobutrol (Gadavist,Gadovist, BAY86-4875); Drug: Gadobutrol (Gadavist,Gadovist, BAY86-4875); Drug: Gadobutrol (Gadavist,Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Completed - verified December 2011 - Condition: Healthy Subjects
Interventions: Drug: Acetylsalicylic Acid (Aspirin, BAY1019036); Drug: Acetaminophen; Drug: Placebo
Sponsors: Bayer; Bayer
Completed - verified October 2011 - Condition: Neoplasms
Interventions: Drug: BAY80-6946; Drug: BAY80-6946
Sponsors: Bayer; Bayer
Active, not recruiting - verified February 2012 - Condition: Osteoporosis, Postmenopausal
Intervention: Drug: E2/LNG oral (Wellnara, BAY86-5029)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Osteoporosis, Postmenopausal
Intervention: Drug: E2 transdermal (Julina, BAY86-5435)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Contraception
Interventions: Drug: LNG-IUS (BAY 86-5028); Drug: 68 mg etonorgestrel implant for subdermal use (Nexplanon)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Conditions: Multiple Sclerosis (MS); Clinically Isolated System (CIS)
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Drug-Induced Liver Injury
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Sponsors: Bayer; Bayer; RTI Health Solutions
Completed - verified September 2011 - Condition: Pain, Postoperative
Interventions: Drug: Naproxen Sodium ER (BAYH6689); Drug: Immediate Release Naproxen Sodium (BAYH6689); Drug: Placebo
Sponsors: Bayer; Bayer
Completed - verified October 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Acarbose (Glucobay ODT, BAYG5421); Drug: Acarbose (Glucobay ODT, BAYG5421); Drug: Acarbose (Glucobay, BAYG5421)
Sponsors: Bayer; Bayer
Completed - verified September 2011 - Condition: Neoplasms
Interventions: Drug: BAY80-6946 + BAY86-9766; Drug: BAY80-6946 + BAY86-9766
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Pulmonary Hypertension
Intervention: Drug: Ventavis inhaled (Iloprost, BAYQ6256)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Pain
Interventions: Drug: Naproxen sodium ER (BAY H6689); Drug: Advil
Sponsors: Bayer; Bayer
Completed - verified September 2011 - Condition: Osteoporosis, Postmenopausal
Intervention: Drug: E2 transdermal (Julina, BAY86-5435)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Underweight
Interventions: Device: LNG-IUS; Device: Implanon; Drug: 30 mcg EE and 150 LNG oral contraceptive (Microvlar); Device: TCu380A copper-intrauterine device; Device: TCu380A intrauterine device
Sponsors: University of Campinas, Brazil; University of Campinas, Brazil; Fundação de Amparo à Pesquisa do Estado de São Paulo
Completed - verified May 2012 - Conditions: Contraceptive Usage; Bleeding Due to Intrauterine Contraceptive Device
Interventions: Device: copper-releasing intrauterine device; Device: ENG-releasing implant; Device: LNG-releasing intrauterine system; Device: LNG-IUS
Sponsors: University of Campinas, Brazil; University of Campinas, Brazil
Active, not recruiting - verified July 2011 - Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Dysmenorrhea
Intervention: Drug: EE20/DRSP(YAZ, BAY86-5300)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Diagnostic Imaging
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Sponsors: Bayer; Bayer
Completed - verified June 2011 - Condition: Rectal Cancer
Interventions: Drug: Sorafenib; Drug: 5-Fluorouracil (5-FU); Radiation: Radiation
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting - verified April 2012 - Condition: Primary Hypertension
Intervention: Drug: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
Sponsors: Bayer; Bayer
Completed - verified July 2011 - Condition: Diabetic Macular Edema
Interventions: Biological: VEGF Trap-Eye; Procedure: Laser treatment
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Bayer
Active, not recruiting - verified February 2012
 |
Bayer - Database of Clinical Trials by Pharmaceutical Companies |
